Latest News | Dr Reddy's to Acquire Select Brands from Glenmark in Russia, Ukraine
Get latest articles and stories on Latest News at LatestLY. Dr Reddy's Laboratories on Saturday said it has inked a pact with Glenmark Pharmaceuticals to acquire its select anti-allergy brands in Russia, Ukraine, Kazakhstan and Uzbekistan.
New Delhi, Nov 28 (PTI) Dr Reddy's Laboratories on Saturday said it has inked a pact with Glenmark Pharmaceuticals to acquire its select anti-allergy brands in Russia, Ukraine, Kazakhstan and Uzbekistan.
The Hyderabad-based company has entered into a definitive agreement with Glenmark to acquire brands Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along-with rights to the trademarks, dossiers and patents for the territories mentioned, Dr Reddy's Laboratories said in a statement.
Also Read | Dimple Kapadia on Christopher Nolan’s Tenet: I Have to See It Three Times More to Completely Understand.
The acquired brands represent two types of products -- mometasone mono product and combination of mometasone with azelastine, which are indicated for the treatment of seasonal and perennial allergic rhinitis, it added.
The company however did not disclose financial details.
Also Read | EPFO Extends Deadline to Submit Life Certificate by Pensioners Till February 28.
"The new brands are a great addition to our product portfolio in Russia, Ukraine, Kazakhstan and Uzbekistan which are important core markets for us. Momat Rino, the largest brand acquired, has recently received OTC registration in Russia and this will enable accelerated access of this product to patients," Dr. Reddy's Laboratories Branded Markets (India and Emerging Markets) CEO M V Ramana said.
The acquired products will further add to the company's strong presence in the anti-allergy segment in these countries, and will also enable it to offer a more comprehensive solution to patients in this area, he added.
In a separate statement, Glenmark Pharmaceuticals Chief Commercial Officer Robert Crockart said: “In line with our strategy to launch Ryaltris, our global anti-allergy brand, in the markets of Russia and other CIS countries, we decided to divest the Momat Rino brand and its extension."
As the company awaits approval to launch Ryaltris in the Russian market, it looks forward to strengthen respiratory franchise in the Russia/CIS region, he added.
"We remain committed to the respiratory space globally," Crockart noted.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)